作者
Yuanyuan Yao,xin zhang,Xiangyu Yang,Shanshan Jia,Xianghao Zuo,Xiaoping Chen
摘要
Background: Resistant hypertension (RH), defined as uncontrolled blood pressure (BP) despite three or more antihypertensive agents including a diuretic, is pathophysiologically driven by increased blood volume and sympathetic overactivity. Although mineralocorticoid receptor antagonists (MRAs) are recommended as effective add-on therapy, their clinical utility is frequently limited by hyperkalemia and endocrine-related adverse effects. Compound reserpine and triamterene tablets, a Chinese-developed quadruple single-pill combination (dihydralazine 12.5 mg, reserpine 0.1 mg, hydrochlorothiazide 12.5 mg, and triamterene 12.5 mg), concurrently attenuate sympathetic activity and reduce sodium-fluid retention, positioning it as a promising therapeutic alternative for RH. Methods: A randomized crossover clinical trial has been conducted to compare the efficacy and safety of compound reserpine and triamterene tablets treatment regimen (two tablets of olmesartan/amlodipine (20 mg/5 mg, OA) + one tablet of compound reserpine and triamterene tablets) with those of a standard regimen (two tablets of OA+ indapamide 2.5 mg+ spironolactone 20 mg) in patients with true RH. Patients were recruited and randomly assigned in a 1:1 ratio to 2 crossover groups. The two groups will receive different combination therapies for 6 weeks, and will then switch to the other combination therapy for 6 weeks, with a 4-week wash-out. The primary outcome was the difference in 24-hour mean systolic blood pressure (SBP) between the two regimens after 6 weeks of intervention. Results: Of the 32 patients with true RH enrolled, 28 completed follow-up (mean age 57.0±9.8 years, 64.3% male), with a baseline 24-hour ambulatory BP of 144.4/88.9 mmHg on 2 OA tablets/day. After 6 weeks, the difference in 24h SBP between the two regimens was -2.28 mmHg (95% CI: -7.12, 2.55, P =0.340), and the upper CI limit was below the margin of 3 mm Hg, confirming the non-inferiority of the compound reserpine and triamterene tablets treatment regimen to the standard regimen. Compared with standard regimen, the study regimen demonstrated numerically higher BP control rates, lower BP load, and reduced heart rate, though differences were not statistically significant (all adjusted P > 0.05). No serious adverse events occurred, and serum uric acid levels were significantly lower with the study regimen than with the standard regimen ( P = 0.041). Conclusion: The compound reserpine and triamterene tablets treatment regimen showed non-inferior antihypertensive efficacy versus standard therapy for true RH, with no obvious neuropsychiatric adverse reactions and milder impact on serum uric acid. Trial registration : Chinese Clinical Trial Registry ChiCTR2400081878. Registered on March 14, 2024. ( http://www.chictr.org.cn )